Literature DB >> 11994350

Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications.

Evangelia Charmandari1, Martina Weise, Stefan R Bornstein, Graeme Eisenhofer, Margaret F Keil, George P Chrousos, Deborah P Merke.   

Abstract

Leptin is secreted by the white adipose tissue and modulates energy homeostasis. Nutritional, neural, neuroendocrine, paracrine, and autocrine factors, including the sympathetic nervous system and the adrenal medulla, have been implicated in the regulation of leptin secretion. Classic congenital adrenal hyperplasia (CAH) is characterized by a defect in cortisol and aldosterone secretion, impaired development and function of the adrenal medulla, and adrenal hyperandrogenism. To examine leptin secretion in patients with classic CAH in relation to their adrenomedullary function and insulin and androgen secretion, we studied 18 children with classic CAH (12 boys and 6 girls; age range 2-12 yr) and 28 normal children (16 boys and 12 girls; age range 5-12 yr) matched for body mass index (BMI). Serum leptin concentrations were significantly higher in patients with CAH than in control subjects (8.1 +/- 2.0 vs. 2.5 +/- 0.6 ng/ml, P = 0.01), and this difference persisted when leptin values were corrected for BMI. When compared with their normal counterparts, children with CAH had significantly lower plasma epinephrine (7.1 +/- 1.3 vs. 50.0 +/- 4.2, P < 0.001) and free metanephrine concentrations (18.4 +/- 2.4 vs. 46.5 +/- 4.0, P < 0.001) and higher fasting serum insulin (10.6 +/- 1.4 vs. 3.2 +/- 0.2 microU/ml, P < 0.001) and testosterone (23.7 +/- 5.3 vs. 4.6 +/- 0.5 ng/dl, P = 0.003) concentrations. Insulin resistance determined by the homeostasis model assessment method was significantly greater in children with classic CAH than in normal children (2.2 +/- 0.3 vs. 0.7 +/- 0.04, P < 0.001). Leptin concentrations were significantly and negatively correlated with epinephrine (r = -0.50, P = 0.001) and free metanephrine (r = -0.48, P = 0.002) concentrations. Stepwise multiple linear regression analysis indicated that serum leptin concentrations were best predicted by BMI in both patients and controls. Gender predicted serum leptin concentrations in controls but not in patients with classic CAH. No association was found between the dose of hydrocortisone and serum leptin (r = -0.17, P = 0.5) or insulin (r = 0.24, P = 0.3) concentrations in children with CAH. Our findings indicate that children with classic CAH have elevated fasting serum leptin and insulin concentrations, and insulin resistance. These most likely reflect differences in long-term adrenomedullary hypofunction and glucocorticoid therapy. Elevated leptin and insulin concentrations in patients with CAH may further enhance adrenal and ovarian androgen production, decrease the therapeutic efficacy of glucocorticoids, and contribute to later development of polycystic ovary syndrome and/or the metabolic syndrome and their complications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994350     DOI: 10.1210/jcem.87.5.8456

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  42 in total

1.  Metabolic disorders in newly diagnosed young adult female patients with simple virilizing 21-hydroxylase deficiency.

Authors:  Hui-Jie Zhang; Jun Yang; Man-Na Zhang; Chang-Qin Liu; Min Xu; Xue-Jun Li; Shu-Yu Yang; Xiao-Ying Li
Journal:  Endocrine       Date:  2010-10-27       Impact factor: 3.633

2.  Increased Abdominal Adiposity in Adolescents and Young Adults With Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  Mimi S Kim; Anna Ryabets-Lienhard; Anh Dao-Tran; Steven D Mittelman; Vicente Gilsanz; Sheree M Schrager; Mitchell E Geffner
Journal:  J Clin Endocrinol Metab       Date:  2015-06-10       Impact factor: 5.958

3.  Leptin Elevation as a Risk Factor for Slipped Capital Femoral Epiphysis Independent of Obesity Status.

Authors:  Schuyler J Halverson; Tracy Warhoover; Gregory A Mencio; Steven A Lovejoy; Jeffrey E Martus; Jonathan G Schoenecker
Journal:  J Bone Joint Surg Am       Date:  2017-05-17       Impact factor: 5.284

4.  Adrenomedullary function in patients with nonclassic congenital adrenal hyperplasia.

Authors:  S Verma; L Green-Golan; C VanRyzin; B Drinkard; S P Mehta; M Weise; G Eisenhofer; D P Merke
Journal:  Horm Metab Res       Date:  2010-05-05       Impact factor: 2.936

5.  Bioelectrical impedance analysis of body fatness in childhood congenital adrenal hyperplasia and its metabolic correlates.

Authors:  Pinar Isguven; Ilknur Arslanoglu; Nilgun Mesutoglu; Metin Yildiz; Muferret Erguven
Journal:  Eur J Pediatr       Date:  2008-01-17       Impact factor: 3.183

6.  Mineralocorticoid deficiency and treatment in congenital adrenal hyperplasia.

Authors:  Raja Padidela; Peter C Hindmarsh
Journal:  Int J Pediatr Endocrinol       Date:  2010-05-04

7.  Long-Term Gynecological Outcomes in Women with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  T H Johannsen; C P L Ripa; E Carlsen; J Starup; O H Nielsen; M Schwartz; K T Drzewiecki; E L Mortensen; K M Main
Journal:  Int J Pediatr Endocrinol       Date:  2010-10-20

Review 8.  [Congenital adrenal hyperplasia and growth hormone deficiency. Special care in transition to adulthood].

Authors:  H G Dörr; C Schöfl
Journal:  Internist (Berl)       Date:  2009-10       Impact factor: 0.743

Review 9.  The breast cancer and the environment research centers: transdisciplinary research on the role of the environment in breast cancer etiology.

Authors:  Robert A Hiatt; Sandra Z Haslam; Janet Osuch
Journal:  Environ Health Perspect       Date:  2009-06-16       Impact factor: 9.031

10.  Blood Pressure and Left Ventricular Characteristics in Young Patients with Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  Graziamaria Ubertini; Carla Bizzarri; Armando Grossi; Fabrizio Gimigliano; Lucilla Ravà; Danilo Fintini; Marco Cappa
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.